Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the innovative drug sector is currently the core focus, supported by favorable domestic policies such as the NMPA's "Spring Rain Action" to promote clinical innovation in medical devices [4][5]. - The total amount of innovative drug licensing transactions in China exceeded $60 billion in the first three months of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. - The report suggests focusing on companies with core technology platforms and differentiated pipeline layouts, particularly those expected to achieve positive catalysts at major academic conferences like AACR [5]. Important Industry News - The NMPA has initiated a three-year "Spring Rain Action" to support the transformation of clinical innovation in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has been approved by the FDA, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has received FDA approval, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, making it the first of its kind domestically [46]. Company Dynamics - Novartis plans to invest over 3.3 billion RMB in China to enhance its R&D, production, and operational capabilities [48].

证券代码：688410 证券简称：山外山 公告编号：2026-009 公司于 2026 年 3 月 30 日分别收到股东圆外圆、重庆德祥、重庆德瑞出具的 《关于股份减持计划实施结果的告知函》，以及收到股东圆外圆、重庆德祥、重 庆德瑞和高光勇先生共同出具的《关于权益变动触及 1%刻度的告知函》。在本 次减持计划期间，股东圆外圆、重庆德祥、重庆德瑞通过集中竞价交易和大宗交 易的方式累计减持公司股份 6,374,710 股，减持股份数量占公司总股本的 2.00%。 本次减持计划已实施完毕且权益变动触及 1%刻度。 重庆山外山血液净化技术股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度暨减持 股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次减持计划实施前，重庆圆外圆商业管理合伙企业（有限合伙）（以下简 称"圆外圆"）、重庆德祥商业管理合伙企业（有限合伙）（以下简称"重庆德 祥"）、重庆德瑞商业管理合伙企业（有限合伙）（以下简称"重庆德瑞"）均 为重庆山外山 ...

重庆山外山血液净化技术股份有限公司（以下简称"公司"）全资子公司重庆天外 天生物技术有限公司于近日收到由国家药品监督管理局颁发的《中华人民共和国医疗器 械注册证》，具体情况公告如下： 上述产品注册证的取得，标志着公司在丰富血液净化耗材产品线、加速在研产品商 业化进程方面迈出关键一步，取得又一重要成果。该产品的获批将有效满足市场日益多 元化的临床需求，进一步完善公司血液净化领域的产品布局，并有望带动相关产品的协 同销售，增强整体市场竞争力。对公司持续提升核心竞争力、巩固行业地位具有积极意 义。 三、风险提示 证券代码：688410 证券简称：山外山 公告编号：2026-008 重庆山外山血液净化技术股份有限公司 关于自愿披露全资子公司取得医疗器械注册证的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、医疗器械注册证的具体情况 | 注册人名称 | 重庆天外天生物技术有限公司 | | --- | --- | | 注册人住所 | 重庆市两江新区慈济路1号 | | 生产地址 | 重庆市两江新区慈济路1号C栋5楼 | | 产品 ...

Core Viewpoint - The company, Shanwaishan, reported significant growth in both revenue and profit for 2025, with revenue reaching 806.82 million yuan, a 42.23% increase year-on-year, and net profit doubling to 143.12 million yuan, reflecting a 101.89% growth. The non-recurring net profit surged by 141.34%, indicating a substantial improvement in profitability [1][4][10]. Group 1: Financial Performance - The company's revenue for 2025 was 806.82 million yuan, up from 567.27 million yuan in 2024, marking a 42.23% increase [4][6]. - The net profit attributable to shareholders reached 143.12 million yuan, compared to 70.89 million yuan in the previous year, representing a 101.89% increase [4][6]. - The non-recurring net profit was 137.99 million yuan, significantly higher than 57.18 million yuan in 2024, with a growth rate of 141.34% [4][6][10]. Group 2: Profitability Drivers - The faster growth of profit compared to revenue is attributed to structural changes and economies of scale [2][3]. - Key factors for profit growth include sustained equipment sales, a significant increase in consumable revenue, reduced unit costs due to higher production volumes, and improved gross margins [5][10]. - The shift from selling equipment to consumables represents a transition to a more profitable business model, where consumables provide recurring revenue [7][8]. Group 3: Business Model Evolution - The company is moving from a model focused on one-time equipment sales to one that emphasizes ongoing consumable sales, which enhances profitability [8][17]. - As consumables become a larger part of revenue, the company benefits from lower fixed costs per unit, leading to higher profit margins [9][10]. - This transition indicates a shift in growth logic from acquiring orders to focusing on existing installations and consumable usage [18][19]. Group 4: Future Considerations - The sustainability of profit growth will depend on the ability to maintain installation volumes, increase consumable penetration rates, and continue reducing unit costs [20][21]. - The 2025 performance signals that growth is increasingly driven by structural improvements rather than just scale [22].

Core Viewpoint - The blood dialysis machine market in China is experiencing rapid growth, with the market size expected to reach 4.131 billion yuan by 2025, reflecting a year-on-year increase of 6.4% [1][6]. Industry Overview - Blood dialysis machines, also known as artificial kidneys, are essential medical devices for treating renal failure and uremia, consisting of a blood monitoring alarm system and a dialysis liquid supply system [3][4]. - The increasing elderly population and rising prevalence of chronic kidney diseases are driving the demand for blood dialysis machines [5][6]. Market Size and Growth - The market size for blood dialysis machines in China is projected to grow significantly, driven by an aging population and an increasing number of patients requiring dialysis treatment [1][6]. - The number of patients undergoing dialysis in China is expected to rise from 385,100 in 2015 to 1,027,300 by 2024, with male patients making up a significant portion of this demographic [5][6]. Competitive Landscape - The Chinese blood dialysis machine industry is primarily dominated by foreign companies such as Fresenius Medical, B. Braun, Baxter, and Nipro, indicating substantial room for domestic companies to capture market share [7][8]. - Domestic companies are enhancing their R&D capabilities, leading to improvements in technology and product quality, which positions them to compete more effectively against international brands [7][8]. Industry Development Trends - The process of domestic substitution for blood dialysis machines is accelerating, with local companies focusing on core technology and key component development to reduce reliance on foreign brands [10][11]. - Future technological advancements in blood dialysis machines will focus on smart and precise upgrades, integrating IoT and AI for improved monitoring and safety [11][12]. - The application scenarios for blood dialysis machines are expanding beyond traditional hospitals to include community healthcare settings and home dialysis solutions, driven by the increasing demand for accessible and convenient treatment options [12].

Core Viewpoint - The company reported significant growth in revenue and net profit for the fiscal year 2025, indicating strong performance in the blood purification equipment market [1] Financial Performance - The company achieved total operating revenue of 807 million yuan, an increase of 42.23% compared to the same period last year [1] - The net profit attributable to the parent company was 143 million yuan, reflecting a substantial increase of 101.89% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 138 million yuan, which represents a 141.34% increase compared to the previous year [1] Market Position and Product Performance - The company is a leading player in the domestic blood purification equipment sector, benefiting from technological advantages and strong brand recognition [1] - The market share of the company's products has been steadily increasing, contributing to the growth in sales revenue of blood purification equipment [1] - Sales revenue from self-produced blood purification consumables saw a significant increase during the reporting period [1] Cost and Profitability - With the increase in production and sales volume, the fixed cost per unit of self-produced consumables has decreased, leading to an improvement in gross profit margin [1] - Overall profitability of the company has strengthened as a result of these factors [1]

Group 1 - The company reported a total operating revenue of 806.82 million yuan for the year 2025, representing a year-on-year growth of 42.23% [2] - The net profit attributable to the owners of the parent company reached 143.12 million yuan, showing a significant year-on-year increase of 101.89% [2]

Financial Performance - The total operating revenue for 2025 reached ¥806.82 million, an increase of 42.23% compared to the previous year[3] - The net profit attributable to the parent company was ¥143.12 million, reflecting a growth of 101.89% year-on-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was ¥137.99 million, up 141.34% from the previous year[3] - Basic earnings per share increased to ¥0.4456, a rise of 100.99% compared to the same period last year[3] Assets and Equity - The total assets at the end of the reporting period were ¥2,332.17 million, a 15.94% increase from the beginning of the period[5] - The equity attributable to the parent company was ¥1,776.18 million, growing by 5.28% from the start of the period[5] Profitability and Market Position - The gross profit margin improved due to a decrease in unit fixed costs as production volume increased, enhancing overall profitability[5] - The company maintained its position as a leading domestic blood purification equipment manufacturer, benefiting from technological advantages and strong brand effects[6] - The sales revenue of self-produced blood purification consumables significantly increased during the reporting period[6] Reporting Accuracy - There are no major uncertainties affecting the accuracy of the performance report as of the announcement date[7]

Core Insights - The company is projected to achieve an operating revenue of 806.82 million yuan in 2025, representing a 42.23% increase compared to the previous year [1] - The net profit attributable to the parent company's owners is expected to reach 143.12 million yuan, marking a significant increase of 101.89% year-on-year [1] - The net profit attributable to the parent company's owners, excluding non-recurring gains and losses, is forecasted to be 137.99 million yuan, reflecting a substantial increase of 141.34% compared to the same period last year [1]

Core Viewpoint - The company, Shanwaishan (688410.SH), reported a significant equity change involving its shareholders, indicating a reduction in shareholding by certain entities associated with the company [1] Group 1: Shareholder Actions - Shareholders Yuanwaiyuan, Chongqing Dexiang, and Chongqing Derui collectively reduced their holdings by 997,400 shares, which represents 0.31% of the company's total share capital [1] - The share reductions occurred between February 4 and February 12, 2026, with specific reductions of 546,000 shares, 243,000 shares, and 209,800 shares respectively [1] - The aforementioned shareholders are part of the company's employee stock ownership platform, and the company's controlling shareholder and actual controller, Gao Guangyong, is the managing partner of this platform, indicating a concerted action relationship among them [1]